3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Recurrence
1
Prostatic Neoplasms
1
Neurofibromatosis 1
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Advanced Solid Tumors
1
Interventions
AZD 6244
3
mirdametinib
2
Sirolimus
2
Inhalation
2
Everolimus
2
Acetylcysteine
2
trametinib
1
tipifarnib
1
pirfenidone
1
peginterferon alfa-2b
1
omipalisib
1
cediranib
1
binimetinib
1
Vincristine
1
Vinblastine
1
Temozolomide
1
Surveys and Questionnaires
1
Sunitinib
1
Radiotherapy
1
N-monoacetylcystine
1
Methotrexate
1
Magnetic Resonance Imaging
1
Lovastatin
1
Lenalidomide
1
Ifosfamide
1
Gadolinium DTPA
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Etoposide
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neurofibromatosis 1
×
Dosage Forms
×
Clear all
NCT05309668
2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2
Active not recruiting
36 enrolled
37 charts